Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study JM Soto, JT Toledo, P Gutierrez … [et.al]
Tipo de material:
No hay ítems correspondientes a este registro
We studied the efficacy of WR279396, a topical formulation of aminoglycosides that cures 100 per cent of cutaneous leishmaniasis lesions in mice. We conducted what is to our knowledge the first controlled study of WR279396 therapy for clinical cutaneous l
No hay comentarios en este titulo.
Ingresar a su cuenta para colocar un comentario.